Annovis Bio Reports Promising Phase III Study Results for Buntanetap in Parkinson’s Disease Treatment

1. Phase III Study Results: Annovis Bio has announced positive results from its Phase III study on buntanetap, a drug candidate for treating Parkinson's Disease (PD). The study demonstrated improvements in both motor and non-motor functions, as well as cognitive abilities in PD patients, particularly those with a diagnosis of over three years.
2. Cognitive Function: Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Patients with substantial cognitive decline exhibited a very pronounced improvement.
3. MDS-UPDRS Scores: The study demonstrated significant improvements in MDS-UPDRS Part II, Part III, Part II+III, and Total scores in Parkinson's patients with a diagnosis of over three years and in those with Postural Instability and Gait Difficulties (PIGD).
4. Safety Profile: The safety profile of buntanetap remained consistent across all study participants, aligning with previous data from Alzheimer's disease studies.
5. Future Studies: Annovis Bio plans to advance buntanetap into longer studies to explore its disease-modifying properties further.
6. Investor Webcast: The company hosted a webcast to discuss the study findings in detail.
7. Market Impact: Annovis Bio's stock experienced significant volatility following the announcement, with a price decrease of 19.54% over the last month and 52.86% over the last three months, indicating a period of bearish sentiment among investors.